Arcturus Therapeutics Ltd (ARCT) Stock Price, Quote & News

Company Profile

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10628 Science Center Drive, Suite 250, San Diego, United States

wahoowa96 Nov. 8 at 3:17 AM

$ARCT Will be glorious to gap-fill to 24 after sharing secret impromptu slide of 15 mg ARCT-032 showing shocking ppFEV and HRCT images of mucus plugs clearing on the third cohort 6 people group such that the line crossed the upper boundary line of variance ppFEV and continued on...those plugs on the upper lungs 🫁 were disappearing. 🤣🤣🤣 Have a good weekend!!

0 · Reply

bigchouse Nov. 8 at 1:27 AM

$ARCT

0 · Reply

MoneyGroupLLC Nov. 7 at 10:17 PM

Enter: $ARCT Calls Strike Price: $10 Expiry Date: DEC 19 2025 Buy in Price: $0.50 - $0.65 Sell Price: $0.91 Profit : +81% (Turn every $1 into $1.81) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

2PacalypseNow4Life Nov. 7 at 8:56 PM

$ARCT dont forget about arct-2138 and arct-2304.

0 · Reply

wahoowa96 Nov. 7 at 7:42 PM

$ARCT Hey Penetrated 12's will attack 11-12.

0 · Reply

Dr_Feel_Good Nov. 7 at 7:40 PM

$ARCT she’s recoiling… lets fkn go.. Happy Friday ARCT Fam

1 · Reply

wahoowa96 Nov. 7 at 7:32 PM

$ARCT Attacking and penetrating 12's today.

0 · Reply

wahoowa96 Nov. 7 at 7:06 PM

$ARCT Make your move!

1 · Reply

wahoowa95 Nov. 7 at 3:53 PM

$ARCT earnings release on the 10th gonna make this a penny stock

1 · Reply

MaxCorona Nov. 7 at 3:19 PM

$ARCT after earnings 3$. Can not be very good, COVID out of focus, no other products than Kostaive. Rebuy at 3-5 $ to play the CYstic fibrosis gamble.

1 · Reply

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Oct 28, 2025, 4:01 PM EDT - 10 days ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

Oct 22, 2025, 3:05 PM EDT - 16 days ago

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Oct 22, 2025, 8:53 AM EDT - 16 days ago

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Oct 22, 2025, 7:30 AM EDT - 16 days ago

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Aug 11, 2025, 8:16 PM EDT - 3 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript

Aug 11, 2025, 4:01 PM EDT - 3 months ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 3 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 11:00 AM EDT - 4 months ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 4 months ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 7:40 PM EDT - 6 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 6 months ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Apr 22, 2025, 4:01 PM EDT - 7 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 10, 2025, 8:00 AM EDT - 7 months ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 6, 2025, 9:44 PM EST - 8 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:01 PM EST - 8 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 8 months ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 9 months ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 9 months ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 4, 2025, 8:30 AM EST - 9 months ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 10 months ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 10 months ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 10, 2025, 8:00 AM EST - 10 months ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 10 months ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 11 months ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 8:00 PM EST - 1 year ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:44 PM EST - 1 year ago

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 11:24 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 13, 2024, 8:15 AM EDT - 1 year ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 9, 2024, 5:27 AM EDT - 1 year ago

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 5, 2024, 8:50 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 8, 2024, 2:42 AM EDT - 1 year ago

Arcturus: A Hidden Gem In The Biotech Sector

Jun 7, 2024, 10:30 AM EDT - 1 year ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

May 28, 2024, 6:30 AM EDT - 1 year ago

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

May 20, 2024, 8:30 AM EDT - 1 year ago

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

May 8, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Apr 25, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

wahoowa96 Nov. 8 at 3:17 AM

0 · Reply

bigchouse Nov. 8 at 1:27 AM

$ARCT

0 · Reply

MoneyGroupLLC Nov. 7 at 10:17 PM

0 · Reply

2PacalypseNow4Life Nov. 7 at 8:56 PM

$ARCT dont forget about arct-2138 and arct-2304.

0 · Reply

wahoowa96 Nov. 7 at 7:42 PM

$ARCT Hey Penetrated 12's will attack 11-12.

0 · Reply

Dr_Feel_Good Nov. 7 at 7:40 PM

$ARCT she’s recoiling… lets fkn go.. Happy Friday ARCT Fam

1 · Reply

wahoowa96 Nov. 7 at 7:32 PM

$ARCT Attacking and penetrating 12's today.

0 · Reply

wahoowa96 Nov. 7 at 7:06 PM

$ARCT Make your move!

1 · Reply

wahoowa95 Nov. 7 at 3:53 PM

$ARCT earnings release on the 10th gonna make this a penny stock

1 · Reply

MaxCorona Nov. 7 at 3:19 PM

$ARCT after earnings 3$. Can not be very good, COVID out of focus, no other products than Kostaive. Rebuy at 3-5 $ to play the CYstic fibrosis gamble.

1 · Reply

MaxCorona Nov. 7 at 2:51 PM

$ARCT So, I think here is game over. Walking away from this until some news may come. This will take years to go back up to >20. Will play the quantum Game the next months. Bye

1 · Reply

extrodyne Nov. 7 at 2:44 PM

$ARCT wow. from 24 to below 8 in days. And from over 40 to below 8 in weeks. That looks pretty fucking good! /s

1 · Reply

StocksnewbieRo Nov. 7 at 9:23 AM

$ARCT good morning holders!!! Let’s push up again!!

0 · Reply

Iightning Nov. 6 at 10:29 PM

1ightning® Options Trade Alert (Actionable) | Buy $ARCT Nov 21 $10 Call | Enter: $0.66 Exit: $0.93 | Profit: 40.90% ROI | https://1ightning.com

0 · Reply

Theflash88 Nov. 6 at 10:05 PM

$ARCT $VTYX You’re joking, right?

1 · Reply

Theflash88 Nov. 6 at 10:04 PM

$ARCT $VTYX NOT ARTC.

0 · Reply

MoneyGroupLLC Nov. 6 at 9:01 PM

Enter: $ARCT Calls Strike Price: $10 Expiry Date: DEC 19 2025 Buy in Price: $0.60 - $0.65 Sell Price: $1.34 Profit : +123% (Turn every $1 into $2.23) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

wahoowa96 Nov. 6 at 8:56 PM

$ARCT So the Covid vaccines were sought after about half as much as last year per Moderna earnings. Doesn't Kostaive go on sale in EU as well?

0 · Reply

wahoowa96 Nov. 6 at 8:01 PM

$ARCT I am comfortable to buy here and made peace with myself.

0 · Reply

Deepstateexecutive Nov. 6 at 7:28 PM

$ARCT pretty soon it’ll be FOR sale and not ON sale. Load now.

0 · Reply

2PacalypseNow4Life Nov. 6 at 5:42 PM

$ARCT i am wondering if theyre gonna share 3rd cohort (15mg) partial results on monday? i believe they gathered some data by now.. that would be nice..

0 · Reply

TheSleeeve Nov. 6 at 4:33 PM

$ARCT Adding size few here can comprehend. Congrats longs.

0 · Reply

Market Cap	225.12M
Revenue (ttm)	152.31M
Net Income (ttm)	-80.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-53.14%
Debt to Equity Ratio	0.00

Volume	1,177,000
Avg Vol	1,349,690
Day's Range	N/A - N/A
Shares Out	27.16M
Stochastic %K	31%
Beta	2.47
Analysts	Strong Sell
Price Target	$53.75